RESEARCH

COVID-19 Vaccines

and Immune Compromised Patients

A new multicenter study is tracking COVID-19 vaccine responses in patients with hematological malignancies and non-malignant blood diseases who have received cellular therapy.

WHY?

Ensuring the safety of our patients is key to the mission of the National Marrow Donor Program and Be The Match. As the approved mRNA vaccines represent a new technology for vaccines that has not been studied in immune compromised patients, it is critical to understand the safety, efficacy, and durability of responses to all of these vaccines for patients receiving cellular therapies.

Conducted By: CIBMTR® Center for International Blood & Marrow Transplant Research; Blood and Marrow Transplant Clinical Trials Network®

In Collaboration With & Supported By: Leukemia & Lymphoma Society; MMRF Multiple Myeloma Research Foundation; NIH National Cancer Institute; NIH National Heart, Lung, and Blood Institute; ASTCT American Society for Transplantation and Cellular Therapy; labcorp; Fred Hutch Cures Start Here®

WHO?

The study will track

516 patients

who received bone marrow transplant (BMT) or cellular therapy in the last 12 months and receive a COVID-19 vaccination as part of their standard of care. *The study will also collect information on patients receiving booster vaccination.*

WHAT?

PRIMARY OBJECTIVE:

Compare and contrast the immunogenicity of COVID-19 vaccines in patients starting their vaccination course less than six months after HCT/CAR-T with patients starting the vaccination course six to 12 months after HCT/CAR-T.

WHEN?

The study team estimates this observational study will be completed within a year after enrollment commences.

- ~10% PATIENTS ENROLLED — 06/30/21
- ~40% PATIENTS ENROLLED — 09/30/21
- ~70% PATIENTS ENROLLED — 12/31/21
- 100% PATIENTS ENROLLED — 03/31/22

WHERE?



Current participating centers. More participants expected as the study continues.

- St. Louis, MO
- Houston, TX
- Duarte, CA
- Cleveland, OH (2)
- Boston, MA
- Durham, NC
- Seattle, WA
- Milwaukee, WI
- Baltimore, MD
- New York, NY (2)
- Tampa, FL
- Atlanta, GA (2)
- Buffalo, NY
- Stanford, CA
- Ann Arbor, MI
- Lawrence, KS
- Minneapolis, MN
- Chapel Hill, NC
- Richmond, VA
- Winston-Salem, NC
- Coral Gables, FL
- Hackensack, NJ
- Charlotte, NC
- Portland, OR
- Philadelphia, PA
- Morgantown, WV
- Columbus, OH
- Worcester, MA
- Detroit, MI
- State College, PA

Learn more at BeTheMatch.org

FROM THE EXPERTS

It's critical that we understand the response to these vaccines for immunocompromised patients with serious hematological disorders receiving cellular therapies. We know that standard vaccine responses after cellular therapies are diminished, meaning these patients are at increased risk of severe COVID-19 disease and death, so gaining this knowledge is of great importance.

— Jeffery J. Auletta, M.D., Senior Vice President, Patient Outcomes & Experience, NMDP and Chief Scientific Director, CIBMTR NMDP.

Given the absence of data about the immunogenicity of any COVID-19 vaccine and no information about the efficacy of mRNA vaccines among this population, it's imperative to quickly identify correlations of protective vaccine responses from the first wave of vaccinated patients. The infrastructure we develop in this process can be readily expanded to study additional SARS-CoV-2 vaccines as they become available.

— Mary M. Horowitz, MD, MS, Principal Investigator of the BMT CTN Data and Coordinating Center.

The ability of the CIBMTR and the BMT CTN to leverage their multicenter research infrastructure to address this important question in a timely manner made us enthusiastic to partner with them.

— Lee Greenberger, PhD, Leukemia and Lymphoma Society (LLS) Chief Scientific Officer.

#BeTheMatch